MedTrace Logo

Zinc Supplementation and Behçet's Syndrome

NCT05098678 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-11-04

No results posted yet for this study

Summary

To study the effects of zinc gluconate supplementation on patients with Behçet's syndrome, 50 patients will be randomly allocated to two groups: placebo group or zinc group (one tablet of 30 mg/day elemental zinc) for 12 weeks. All participants will be asked not to alter their diet, medication, and physical activity during the study. At the first and the end of the intervention, genes and proteins expression, the serum level of inflammatory factors, quality of life, disease activity, anthropometric measures, physical activity and serum level of zinc will be assessed and compared between groups.

Conditions

  • Behcet Syndrome

Interventions

DIETARY_SUPPLEMENT

Zinc gluconate

120 mg each tablet containing 30 mg elemental zinc

DIETARY_SUPPLEMENT

Placebo

Placebo (microcrystalline cellulose): 1 tablet (120 mg each)

Sponsors & Collaborators

  • Tabriz University of Medical Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-22
Primary Completion
2021-05-22
Completion
2021-09-22

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05098678 on ClinicalTrials.gov